More on Myriad Genetics (MYGN): FQ2 easily beats Street estimates on a 21% Y/Y jump in total...

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

More on Myriad Genetics (MYGN): FQ2 easily beats Street estimates on a 21% Y/Y jump in total sales. Molecular diagnostic testing revenue +20%, Oncology +16%, and Women's Health +27% over the prior year period. The company raises FY13 guidance, now expecting to earn between $1.55 - $1.58 per share on revenue of around $575M to $585M. Street estimates are for an EPS of $1.54 on revenue of $580M. Shares +1.3% AH.